Aim of this study was to develop and validate a Sinhala version of the CLDQ (sCLDQ) and to test its correlation with the degree of liver dysfunction in a cohort of Sri Lankan patients with cirrhosis. Methods: A standard translation method was used to develop the sCLDQ. Pilot testing was done with relevant cultural and language adaptations. The final version was self-administered to stable CLD patients, together with the WHO Quality of Life-BREF (WHOQOL-BREF) validated Sinhala version, for comparison. Epacadostat order sCLDQ was re-administered 4 weeks
later to test internal consistency and reliability. The validation was assessed by Cronabach’s alpha, intraclass correlation coefficient (ICC) and Pearson’s correlation coefficient. ANOVA and Pearson’s correlation were used to test correlation with the degree of liver dysfunction. Results: Validation was done with 214 subjects, mean age 55.6 (SD 10.4) years; male 77.6%. Overall Cronabach’s alpha was
0.926. Itra-class correlations varied from 0.431 to 0.912 and all were significant (p 0.000). Retesting was done on a sub-sample of 18 subjects. Test-retest correlation was 0.695 (p 0.008). WHO-BREF was applied on a sub-sample of 48 subjects. There was a significant correlation (Pearson’s r = 0.391; p = 0.004) between sCLDQ and WHOQOL BREF. sCLDQ was significantly Wnt tumor associated with MELD (r = −0.13; p = 0.038), MELD Sodium (r = −0.223; p = 0.002), Bilirubin (r = −0.124; p = 0.036), Serum Sodium (r = 0.172; p = 0.009), Serum Albumin (r = 0.201; p = 0.003) and Child grade (f = 3.687; p = 0.027). Conclusion: sCLDQ is a reliable and valid
tool to assess Glycogen branching enzyme QoL of Sri Lankan cirrhotics and correlates well with known indices of disease severity. Key Word(s): 1. Cirrhosis; 2. CLDQ; 3. Sinhala; 4. Quality of Life; Presenting Author: YINPENG JIN Additional Authors: GUANGFENG CHEN, QINGCHUN FU, XIAOQING LIU, CHENGWEI CHEN, HENG ZHOU Corresponding Author: QINGCHUN FU, XIAOQING LIU, CHENGWEI CHEN Affiliations: Shanghai Liver Diseases Research Center, the Nanjing Military Command; Tongji University Objective: Acute liver failure is a highly lethal disease with rare effective therapeutic methods. Allogeneic liver transplantation is a viable treatment for acute liver failure. However, there is a serious shortage of liver donors. Stem cell transplantation is a more promising alternative approach for acute liver failure. Here we show that the human adipose-derived stem cells (hADSCs) have promising therapeutic potential for rats with acute liver failure. Methods: HADSCs were isolated from fat tissue, purified by adherence screening method and cultured in serum-free medium.